Equip
Equip provides virtual, evidence-based eating disorder treatment at home, using a five-person care team for each patient.
Secondary Market Price
Secondary Market Price
How Equip Measures Up
To help you manage your Equip equity, Prospect has run the company through our machine learning model.
Prospect Rating
TBD
We're currently analyzing the data to establish our rating for Equip. Check back soon to see our forecast for the company's value in four years.
Exit Risk
TBD
We are still gathering data on Equip to train our machine learning model. Check back soon for our exit risk rating for Equip!
Funding Stage
Series C
For a potential employee, Equip's Series C status suggests a company that has moved past the initial startup risks and is now focused on scaling its proven business model. This means you'd be joining a more stable environment that still offers significant opportunities for growth as the company expands.
Secondary Market Price Chart
Create a free account to unlock real-time secondary market prices and future projections of Equip's value.
Sign up to Unlock the Latest DataData will be available soon.
Sign up to receive notifications when it is available.
Prospect Projected Future Equip Prices
Prospect’s machine learning model has been trained on the same data top-tier investors use to project the likely range of outcomes for Equip's equity. Create a free account to view 10th-90th percentile projections over 2, 4, and 6 years.
Powerful tools to earn more from your equity
Company Description
Equip is a health technology company that provides virtual treatment programs for eating disorders. The company’s services are delivered remotely to patients in their homes, using a five-person care team that consists of a therapist, dietitian, physician, peer mentor, and family mentor. Founded in 2019 by Kristina Saffran and Erin Parks, the San Diego-based company was originally known as Barcada Health. Since its inception, Equip has grown to a staff of over 250 employees.
The company plans to continue expanding access to its virtual treatment model and is actively involved in research and industry events. Recent announcements include its recognition by TIME as one of the World’s Top HealthTech Companies of 2025 and its inclusion on Fast Company’s list of the Best Workplaces for Innovators. Equip has also published research on eating disorders in the Latinx community and has raised significant capital to support its growth, with total funding reported to be around $189 million across several rounds. The leadership team has also expanded, with recent appointments including a new Vice President of Medical Operations and Quality.
- Tiger Global
- General Catalyst
- F-Prime
- Optum
- .406 Ventures
- TCG
- Co-Founder, CEO Kristina Saffran
- Co-Founder, Chief Clinical Officer Erin Parks
Peer Group Comparison
Vs Peer Group of >$4B Startups
Frequently Asked Questions
Joining Anduril as an employee is another way to acquire equity, typically through stock options included in compensation packages.
Is Prospect worth joining?
Evaluating whether a startup is worth joining depends on its growth potential and your personal career goals. Platforms like Prospect provide data-driven tools to help you assess a company's potential by analyzing metrics similar to those used by venture capitalists.
What should I do with my Prospect stock?
Managing private company stock involves creating a strategy for exercising options and planning for taxes to maximize your potential returns. Tools offered by Prospect can help you model different scenarios and create a personalized plan for your equity.
Can you sell Prospect stock?
As Prospect is a private company, its stock is not traded on a public exchange, but selling may be possible through company-approved tender offers or on secondary markets. Platforms like Prospect offer tools to help employees navigate these sales and identify tax-optimal shares to sell.
How can I find the value of my Prospect stock?
The value of private stock is typically based on the company's most recent 409A valuation, but its future worth can be projected using various data points. You can use a platform like Prospect, which leverages predictive models and an equity calculator to help you forecast the potential value of your holdings.
What is Prospect's equity worth?
As a private company, Prospect's valuation is not publicly disclosed and is typically determined by the price set during its most recent funding round. This information is usually shared with employees and investors but is not available to the general public.
What is Prospect's stock ticker symbol?
Prospect is a private company and is not traded on a public stock exchange, so it does not have a stock ticker symbol. Ticker symbols are assigned to companies only when they become publicly listed through an Initial Public Offering (IPO).
Can I buy or sell Prospect stock?
Since Prospect is a private company, its stock is not available for purchase by the general public on stock markets. Buying or selling shares is generally limited to accredited investors during specific funding rounds or through secondary market transactions, which are subject to company approval.
What is the criteria to buy or invest in Prospect stock?
Investing in a private company like Prospect is typically reserved for accredited investors, venture capital firms, and other institutional investors during formal fundraising rounds. These opportunities are not generally open to the public, unlike investing in publicly traded companies.
